Search

Your search keyword '"D'Alessandria, Calogero"' showing total 258 results
Start Over Author "D'Alessandria, Calogero"
258 results on '"D'Alessandria, Calogero"'

6. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study

Author

Gafita, Andrei, Calais, Jeremie, Grogan, Tristan R, Hadaschik, Boris, Wang, Hui, Weber, Manuel, Sandhu, Shahneen, Kratochwil, Clemens, Esfandiari, Rouzbeh, Tauber, Robert, Zeldin, Anna, Rathke, Hendrik, Armstrong, Wesley R, Robertson, Andrew, Thin, Pan, D'Alessandria, Calogero, Rettig, Matthew B, Delpassand, Ebrahim S, Haberkorn, Uwe, Elashoff, David, Herrmann, Ken, Czernin, Johannes, Hofman, Michael S, Fendler, Wolfgang P, and Eiber, Matthias

Published
2021
Full Text
View/download PDF

7. Comparative Analysis of Morphological and Functional Effects of 225Ac- and 177Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands

Author

Feuerecker, Benedikt, primary, Gafita, Andrei, additional, Langbein, Thomas, additional, Tauber, Robert, additional, Seidl, Christof, additional, Bruchertseifer, Frank, additional, Gschwendt, Jürgen E., additional, Weber, Wolfgang A., additional, D’Alessandria, Calogero, additional, Morgenstern, Alfred, additional, and Eiber, Matthias, additional

Published
2023
Full Text
View/download PDF

10. Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.

Author

Wurzer, Alexander, De Rose, Francesco, Fischer, Sebastian, Schwaiger, Markus, Weber, Wolfgang, Nekolla, Stephan, Wester, Hans-Jürgen, Eiber, Matthias, and D'Alessandria, Calogero

Subjects
MEDICAL dosimetry, PROSTATE cancer, SERUM albumin, EXTERNAL beam radiotherapy, STEREOISOMERS, ISOMERS
Abstract

Background: Radiohybrid PSMA-targeted ligands (rhPSMA) have been introduced as a novel platform for theranostic applications. Among a variety of rhPSMA-ligands developed for radioligand therapy, two stereoisomers [177Lu]Lu-rhPSMA-10.1 and -10.2 have been synthesized and initially characterized in preclinical experiments with the aim to provide an optimized binding profile to human serum albumin, a reduction of charge, and thus accelerated kidney excretion, and unaffected or even improved tumor uptake. As both isomers showed similar in vitro characteristics and tumor uptake at 24 h post injection in tumor bearing mice and in order to identify the isomer with the most favorable pharmacokinetics for radioligand therapy, we carried out in-depth biodistribution and dosimetry studies in tumor-bearing and healthy mice. Results: rhPSMA-10.1 and -10.2 were radiolabeled with lutetium-177 according to the established procedures of other DOTA-based PSMA ligands and displayed a high and comparable stability in all buffers and human serum (> 97%, 24 h). Biodistribution studies revealed fast clearance from the blood pool (0.3–0.6%ID/g at 1 h) and other background tissues within 48 h. Distinctive differences were found in the kidneys, where [177Lu]Lu-rhPSMA-10.1 displayed lower initial uptake and faster excretion kinetics compared to [177Lu]Lu-rhPSMA-10.2 expressed by a 1.5-fold and ninefold lower uptake value at 1 h and 24 h in healthy animals, respectively. Tumor uptake was comparable and in the range of 8.6–11.6%ID/g for both isomers over 24 h and was maintained up to 168 h at a level of 2.2 ± 0.8 and 4.1 ± 1.4%ID/g for [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2, respectively. Conclusion: Our preclinical data on biodistribution and dosimetry indicate a more favorable profile of [177Lu]Lu-rhPSMA-10.1 compared to [177Lu]Lu-rhPSMA-10.2 for PSMA-targeted radioligand therapy. [177Lu]Lu-rhPSMA-10.1 shows fast kidney clearance kinetics resulting in excellent tumor-to-organ ratios over a therapy relevant time course. Meanwhile, [177Lu]Lu-rhPSMA-10.1 is currently being investigated in clinical phase I/II studies in patients with mCRPC (NCT05413850), in patients with high-risk localized PC (NCT06066437, Nautilus Trial) and after external beam radiotherapy (NCT06105918). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of177Lu-PSMA I&T

Author

Karimzadeh, Amir, primary, Soeiro, Paula, additional, Feuerecker, Benedikt, additional, Hecker, Charlotte-Sophie, additional, Knorr, Karina, additional, Heck, Matthias M., additional, Tauber, Robert, additional, D’Alessandria, Calogero, additional, Weber, Wolfgang A., additional, Eiber, Matthias, additional, and Rauscher, Isabel, additional

Published
2023
Full Text
View/download PDF

12. The Impact of PSMA PET–Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy

Author

Karimzadeh, Amir, primary, Heck, Matthias, additional, Tauber, Robert, additional, Solaris, Esteban, additional, Nekolla, Stephan, additional, Knorr, Karina, additional, Haller, Bernhard, additional, D’Alessandria, Calogero, additional, Weber, Wolfgang A., additional, Eiber, Matthias, additional, and Rauscher, Isabel, additional

Published
2023
Full Text
View/download PDF

13. Comparative Analysis of Morphological and Functional Effects of 225 Ac- and 177 Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands.

Author

Feuerecker, Benedikt, Gafita, Andrei, Langbein, Thomas, Tauber, Robert, Seidl, Christof, Bruchertseifer, Frank, Gschwendt, Jürgen E., Weber, Wolfgang A., D'Alessandria, Calogero, Morgenstern, Alfred, and Eiber, Matthias

Subjects
SALIVARY glands, FUNCTIONAL analysis, COMPARATIVE studies, SMALL molecules, LUTETIUM compounds
Abstract

Most Prostate Specific Membrane Antigens (PSMAs) targeting small molecules accumulate in the salivary glands (SGs), raising concerns about SG toxicity, especially after repeated therapies or therapy with 225Ac-labeled ligands. SG toxicity is assessed clinically by the severity of patient-reported xerostomia, but this parameter can be challenging to objectively quantify. Therefore, we explored the feasibility of using SG volume as a biomarker for toxicity. In 21 patients with late-stage metastatic resistant prostate cancer (mCRPC), the PSMA volume and ligand uptake of SG were analyzed retrospectively before and after two cycles of 177Lu-PSMA (LuPSMA; cohort A) and before and after one cycle of 225Ac-PSMA-617 (AcPSMA, cohort B). Mean Volume-SG in cohort A was 59 ± 13 vs. 54 ± 16 mL (−10%, p = 0.4), and in cohort B, it was 50 ± 13 vs. 40 ± 11 mL (−20%, p = 0.007), respectively. A statistically significant decrease in the activity concentration in the SG was only observed in group B (SUVmean: 9.2 ± 2.8 vs. 5.3 ± 1.8, p < 0.0001; vs. A: SUVmean: 11.2 ± 3.3 vs. 11.1 ± 3.5, p = 0.8). SG volume and PSMA-ligand uptake are promising markers to monitor the SG toxicity after a PSMA RLT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study

Author

Autenrieth, Michael E., Seidl, Christof, Bruchertseifer, Frank, Horn, Thomas, Kurtz, Florian, Feuerecker, Benedikt, D’Alessandria, Calogero, Pfob, Christian, Nekolla, Stephan, Apostolidis, Christos, Mirzadeh, Saed, Gschwend, Jürgen E., Schwaiger, Markus, Scheidhauer, Klemens, and Morgenstern, Alfred

Published
2018
Full Text
View/download PDF

16. Data from Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG24-DFO[89Zr] for Tumor-Specific PET/CT Imaging

Author

Stangl, Stefan, primary, Tei, Lorenzo, primary, De Rose, Francesco, primary, Reder, Sybille, primary, Martinelli, Jonathan, primary, Sievert, Wolfgang, primary, Shevtsov, Maxim, primary, Öllinger, Rupert, primary, Rad, Roland, primary, Schwaiger, Markus, primary, D'Alessandria, Calogero, primary, and Multhoff, Gabriele, primary

Published
2023
Full Text
View/download PDF

17. Data from Immuno-PET Imaging of Engineered Human T Cells in Tumors

Author

Mall, Sabine, primary, Yusufi, Nahid, primary, Wagner, Ricarda, primary, Klar, Richard, primary, Bianchi, Henrique, primary, Steiger, Katja, primary, Straub, Melanie, primary, Audehm, Stefan, primary, Laitinen, Iina, primary, Aichler, Michaela, primary, Peschel, Christian, primary, Ziegler, Sibylle, primary, Mustafa, Mona, primary, Schwaiger, Markus, primary, D'Alessandria, Calogero, primary, and Krackhardt, Angela M., primary

Published
2023
Full Text
View/download PDF

19. The prognostic role of68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy

Author

Lunger, Lukas, primary, Chantadisai, Maythinee, additional, Karimzadeh, Amir, additional, Rauscher, Isabel, additional, D'Alessandria, Calogero, additional, Feuerecker, Benedikt, additional, Langbein, Thomas, additional, Tauber, Robert, additional, Schiele, Stefan, additional, Weber, Wolfgang Andreas, additional, and Eiber, Matthias, additional

Published
2022
Full Text
View/download PDF

26. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Author

Balma, Michele, primary, Liberini, Virginia, additional, Racca, Manuela, additional, Laudicella, Riccardo, additional, Bauckneht, Matteo, additional, Buschiazzo, Ambra, additional, Nicolotti, Daniele Giovanni, additional, Peano, Simona, additional, Bianchi, Andrea, additional, Albano, Giovanni, additional, Quartuccio, Natale, additional, Abgral, Ronan, additional, Morbelli, Silvia Daniela, additional, D'Alessandria, Calogero, additional, Terreno, Enzo, additional, Huellner, Martin William, additional, Papaleo, Alberto, additional, and Deandreis, Désirée, additional

Published
2022
Full Text
View/download PDF

33. Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer

Author

Feuerecker, Benedikt, primary, Chantadisai, Maythinee, additional, Allmann, Anne, additional, Tauber, Robert, additional, Allmann, Jakob, additional, Steinhelfer, Lisa, additional, Rauscher, Isabel, additional, Wurzer, Alexander, additional, Wester, Hans-Jürgen, additional, Weber, Wolfgang A., additional, d’Alessandria, Calogero, additional, and Eiber, Matthias, additional

Published
2021
Full Text
View/download PDF

34. Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer

Author

Birindelli, Gabriele, primary, Drobnjakovic, Milos, additional, Morath, Volker, additional, Steiger, Katja, additional, D’Alessandria, Calogero, additional, Gourni, Eleni, additional, Afshar-Oromieh, Ali, additional, Weber, Wolfgang, additional, Rominger, Axel, additional, Eiber, Matthias, additional, and Shi, Kuangyu, additional

Published
2021
Full Text
View/download PDF

35. Nomograms to predict outcomes after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer : An international, multicentre, retrospective study

Author

Gafita, Andrei, Calais, Jeremie, Grogan, Tristan R., Hadaschik, Boris, Wang, Hui, Weber, Manuel, Sandhu, Shahneen, Kratochwil, Clemens, Esfandiari, Rouzbeh, Tauber, Robert, Zeldin, Anna, Rathke, Hendrik, Armstrong, Wesley R., Robertson, Andrew, Thin, Pan, D'Alessandria, Calogero, Rettig, Matthew B., Delpassand, Ebrahim S., Haberkorn, Uwe, Elashoff, David, Herrmann, Ken, Czernin, Johannes, Hofman, Michael S., Fendler, Wolfgang, and Eiber, Matthias

Subjects
Medizin, urologic and male genital diseases
Abstract

Background: Lutetium-177 (¹⁷⁷Lu) prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after ¹⁷⁷Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed to develop nomograms to predict outcomes after ¹⁷⁷Lu-PSMA in patients with mCRPC. Methods: In this multicentre, retrospective study, we screened patients with mCRPC who had received ¹⁷⁷Lu-PSMA between Dec 10, 2014, and July 19, 2019, as part of the previous phase 2 trials (NCT03042312, ACTRN12615000912583) or compassionate access programmes at six hospitals and academic centres in Germany, the USA, and Australia. Eligible patients had received intravenous 6·0–8·5 GBq ¹⁷⁷Lu-PSMA once every 6–8 weeks, for a maximum of four to six cycles, and had available baseline [⁶⁸Ga]Ga-PSMA-11 PET/CT scan, clinical data, and survival outcomes. Putative predictors included 18 pretherapeutic clinicopathological and [⁶⁸Ga]Ga-PSMA-11 PET/CT variables. Data were collected locally and centralised. Primary outcomes for the nomograms were overall survival and prostate-specific antigen (PSA)-progression-free survival. Nomograms for each outcome were computed from Cox regression models with LASSO penalty for variable selection. Model performance was measured by examining discrimination (Harrell's C-index), calibration (calibration plots), and utility (patient stratification into low-risk vs high-risk groups). Models were validated internally using bootstrapping and externally by calculating their performance on a validation cohort. Findings: Between April 23, 2019, and Jan 13, 2020, 414 patients were screened; 270 (65%) of whom were eligible and were divided into development (n=196) and validation (n=74) cohorts. The median duration of follow-up was 21·5 months (IQR 13·3–30·7). Predictors included in the nomograms were time since initial diagnosis of prostate cancer, chemotherapy status, baseline haemoglobin concentration, and [⁶⁸Ga]Ga-PSMA-11 PET/CT parameters (molecular imaging TNM classification and tumour burden). The C-index of the overall survival model was 0·71 (95% CI 0·69–0·73). Similar C-indices were achieved at internal validation (0·71 [0·69–0·73]) and external validation (0·72 [0·68–0·76]). The C-index of the PSA-progression-free survival model was 0·70 (95% CI 0·68–0·72). Similar C-indices were achieved at internal validation (0·70 [0·68–0·72]) and external validation (0·71 [0·68–0·74]). Both models were adequately calibrated and their predictions correlated with the observed outcome. Compared with high-risk patients, low-risk patients had significantly longer overall survival in the validation cohort (24·9 months [95% CI 16·8–27·3] vs 7·4 months [4·0–10·8]; p

Published
2021

38. Detection Efficacy of 18F‐rhPSMA‐7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment

Author

Rauscher, Isabel, primary, Karimzadeh, Amir, additional, Schiller, Kilian, additional, Horn, Thomas, additional, D’Alessandria, Calogero, additional, Franz, Charlott, additional, Wörther, Hannah, additional, Nguyen, Noemi, additional, Combs, Stephanie E., additional, Weber, Wolfgang A., additional, and Eiber, Matthias, additional

Published
2021
Full Text
View/download PDF

39. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

Author

Feuerecker, Benedikt, primary, Tauber, Robert, additional, Knorr, Karina, additional, Heck, Matthias, additional, Beheshti, Ali, additional, Seidl, Christof, additional, Bruchertseifer, Frank, additional, Pickhard, Anja, additional, Gafita, Andrei, additional, Kratochwil, Clemens, additional, Retz, Margitta, additional, Gschwend, Jürgen E., additional, Weber, Wolfgang A., additional, D’Alessandria, Calogero, additional, Morgenstern, Alfred, additional, and Eiber, Matthias, additional

Published
2021
Full Text
View/download PDF

40. Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study

Author

Gafita, Andrei, primary, Calais, Jeremie, additional, Grogan, Tristan R., additional, Zeldin, Anna, additional, Hadaschik, Boris, additional, Hui, Wang, additional, Weber, Manuel, additional, Sandhu, Shahneen, additional, Kratochwil, Clemens, additional, Esfandiari, Rouzbeh, additional, Tauber, Robert, additional, Rathke, Hendrik, additional, Armstrong, Wesley R., additional, Robertson, Andrew, additional, Thin, Pan, additional, D&apos;Alessandria, Calogero, additional, Rettig, Matthew B., additional, Delpassand, Ebrahim S., additional, Haberkorn, Uwe, additional, Elashoff, David, additional, Herrmann, Ken, additional, Czernin, Johannes, additional, Hofman, Prof Michael S., additional, Fendler, Wolfgang P., additional, and Eiber, Matthias, additional

Published
2021
Full Text
View/download PDF

41. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (89Zr)-DFO- Galectin3-F(ab')2 mAb

Author

Varasteh, Zohreh, primary, De Rose, Francesco, additional, Mohanta, Sarajo, additional, Li, Yuanfang, additional, Zhang, Xi, additional, Miritsch, Benedikt, additional, Scafetta, Giorgia, additional, Yin, Changjun, additional, Sager, Hendrik B., additional, Glasl, Sarah, additional, Gorpas, Dimitris, additional, Habenicht, Andreas J.R., additional, Ntziachristos, Vasilis, additional, Weber, Wolfgang A., additional, Bartolazzi, Armando, additional, Schwaiger, Markus, additional, and D'Alessandria, Calogero, additional

Published
2021
Full Text
View/download PDF

45. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T

Author

Yusufi, Nahid, primary, Wurzer, Alexander, additional, Herz, Michael, additional, D’Alessandria, Calogero, additional, Feuerecker, Benedikt, additional, Weber, Wolfgang, additional, Wester, Hans-Jürgen, additional, Nekolla, Stephan, additional, and Eiber, Matthias, additional

Published
2020
Full Text
View/download PDF

46. Positive predictive value and correct detection rate of 18F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard

Author

Chantadisai, Maythinee, primary, Buschner, Gabriel, additional, Krönke, Markus, additional, Rauscher, Isabel, additional, Langbein, Thomas, additional, Nekolla, Stephan G., additional, Schiller, Kilian, additional, Heck, Matthias M., additional, Maurer, Tobias, additional, Wurzer, Alexander, additional, Wester, Hans-Juergen, additional, D'Alessandria, Calogero, additional, Weber, Wolfgang, additional, and Eiber, Matthias, additional

Published
2020
Full Text
View/download PDF

47. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3.

Author

Knorr, Karina, Oh, So Won, Krönke, Markus, Wurzer, Alexander, D'Alessandria, Calogero, Herz, Michael, Weber, Wolfgang, Wester, Hans-Jürgen, Eiber, Matthias, Yusufi, Nahid, and Nekolla, Stephan

Subjects
PANCREAS, RADIATION dosimetry, LUNGS, IMAGE quality analysis, SUBMANDIBULAR gland, PAROTID glands, SALIVARY glands
Abstract

Background: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as 18F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of 18F-rhPSMA-7 with that of single diastereoisomer form, 18F-rhPSMA-7.3. Methods: Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10–300 min) post-injection of 25.6 ± 3.6 MBq 18F-rhPSMA-7 or 28.5 ± 4.8 MBq 18F-rhPSMA-7.3 (n = 3–6 mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collected. Percentage of injected dose per gram was calculated. Absorbed doses were estimated with OLINDA/EXM 1.0. 18F-rhPSMA-7 (n = 47) and 18F-rhPSMA-7.3 (n = 33) PET/CT exams were used to estimate human biodistribution. Mean (range) injected activities were 324 (236–424) MBq versus 345 (235–420) MBq, and acquisition times were 84 (42–166) versus 76 (59–122) minutes for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. SUVmean was determined for background (gluteal muscle), normal organs (salivary glands, blood pool, lung, liver, spleen, pancreas, duodenum, kidney, bladder, bone) and up to three representative tumour lesions. Qualitative analyses assessed image quality, non-specific blood pool activity, and background uptake in bone/marrow using 3/4-point scales. Results: Preclinical dosimetry revealed that at 3.5 h and 1 h bladder voiding intervals, the extrapolated total effective doses were 26.6 and 12.2 µSv/MBq for 18F-rhPSMA-7 and 21.7 and 12.8 µSv/MBq for 18F-rhPSMA-7.3 respectively. Human biodistribution of both agents was typical of other PSMA-ligands and broadly similar to each other; SUVmean were 16.9 versus 16.2 (parotid gland), 19.6 versus 19.9 (submandibular gland), 2.0 versus 1.9 (blood pool, p < 0.005), 0.7 versus 0.7 (lungs), 7.0 versus 7.3 (liver), 9.1 versus 8.4 (spleen), 32.4 versus 35.7 (kidney), 2.5 versus 2.8 (pancreas), 10.9 versus 11.0 (duodenum), 1.1 versus 1.3 (bone) and 4.6 versus 2.0 (bladder; p < 0.001) for 18F-rhPSMA-7 versus 18F-rhPSMA-7.3, respectively. Tumour SUVmean was higher for 18F-rhPSMA-7.3 (32.5 ± 42.7, n = 63 lesions) than for 18F-rhPSMA-7 (20.0 ± 20.2, n = 89 lesions). Conclusions: Radiation dosimetry is favourable for both agents. Radiation exposure, assuming a 1 h voiding interval, is less than 5 mSv after injection of 370 MBq. 18F-rhPSMA-7.3 showed significantly lower bladder uptake, and a higher uptake trend in tumours compared with 18F-rhPSMA-7. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive In Vivo Imaging of Thyroid Cancer

Author

Peplau, Emanuel, primary, De Rose, Francesco, additional, Reder, Sybille, additional, Mittelhäuser, Markus, additional, Scafetta, Giorgia, additional, Schwaiger, Markus, additional, Weber, Wolfgang A., additional, Bartolazzi, Armando, additional, Skerra, Arne, additional, and D'Alessandria, Calogero, additional

Published
2020
Full Text
View/download PDF

50. Safety and Efficacy of Ac-225-PSMA-617 in mCRPC after Failure of Lu-177-PSMA

Author

Feuerecker, Benedikt, primary, Knorr, Karina, additional, Beheshti, Ali, additional, Seidl, Christof, additional, D’alessandria, Calogero, additional, Bruchertseifer, Frank, additional, Tauber, Robert, additional, Retz, Margitta, additional, Weber, Wolfgang, additional, Morgenstern, Alfred, additional, and Eiber, Matthias, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results